Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
McKesson
AstraZeneca
Johnson and Johnson
Baxter

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Dermatophagoides farinae

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Dermatophagoides farinae: Patents, clinical trial progress, indications

Dermatophagoides farinae is an investigational drug.

There have been 8 clinical trials for Dermatophagoides farinae. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2019.

The most common disease conditions in clinical trials are Rhinitis, Allergic, Rhinitis, and Inflammation. The leading clinical trial sponsors are National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina, Chapel Hill, and Gachon University Gil Medical Center.

There are twenty-eight US patents protecting this investigational drug and two hundred and sixty-three international patents.

Recent Clinical Trials for Dermatophagoides farinae
TitleSponsorPhase
Anakinra as a Rescue Treatment for Allergic InflammationNational Heart, Lung, and Blood Institute (NHLBI)Phase 1/Phase 2
Anakinra as a Rescue Treatment for Allergic InflammationUniversity of North Carolina, Chapel HillPhase 1/Phase 2
Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway InflammationNational Heart, Lung, and Blood Institute (NHLBI)Phase 1/Phase 2

See all Dermatophagoides farinae clinical trials

Clinical Trial Summary for Dermatophagoides farinae

Top disease conditions for Dermatophagoides farinae
Top clinical trial sponsors for Dermatophagoides farinae

See all Dermatophagoides farinae clinical trials

US Patents for Dermatophagoides farinae

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dermatophagoides farinae   Start Trial Binding of allergens to a solid phase Abbott Laboratories (Abbott Park, IL)   Start Trial
Dermatophagoides farinae   Start Trial Method for controlling dust mites   Start Trial
Dermatophagoides farinae   Start Trial Recombinant 40 KDa Dermatophagoides farinae allergen Fumakilla Limited (Tokyo, JP) Hiroshima University (Hiroshima, JP)   Start Trial
Dermatophagoides farinae   Start Trial Peptide having allergenicity Torii & Co. (Tokyo, JP) Asahi Breweries, Ltd. (Tokyo, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Dermatophagoides farinae

Drugname Country Document Number Estimated Expiration Related US Patent
Dermatophagoides farinae Australia 634647 2010-04-13   Start Trial
Dermatophagoides farinae Australia 7433091 2010-04-13   Start Trial
Dermatophagoides farinae Canada 2039958 2010-04-13   Start Trial
Dermatophagoides farinae European Patent Office 0451800 2010-04-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Mallinckrodt
Baxter
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.